ABVX
Abivax S.A.
$121.99
-1.64%
$9.7B
No data for this timeframe.
Vol
Market Cap$9.7B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders4 funds
Inst. Value$679.8M
Inst. Activity2 buys / 0 sells
SEC Reports1
Press Releases1
Recent Activity
May 22, 2026
SEC
Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release
PRESS-RELEASE — Impact 5/10
Inst.
MORGAN STANLEY — DOUBLED
3,151,994 shares ($425.1M)
Inst.
BANK OF AMERICA CORP — DOUBLED
522,289 shares ($70.4M)
May 22, 2026
earnings
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
<p align="center"><b>Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Int
Mar 23, 2026
Press
Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expense
Impact 6/10
Price Targets
$155.20
+27.2% upside
Strong Buy
Current $121.99
Low $131.00
Median $155.00
High $176.00
10 analysts
$131.00
$176.00
Analyst Ratings
6Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Mar 16, 2026 | Jefferies | INITIATE | Buy |
| Feb 25, 2026 | BTIG | REITERATE | Buy → Buy |
| Feb 24, 2026 | Wedbush | INITIATE | Underperform |
| Jan 9, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.74 | $-0.75 — $-0.73 | 17% YoY | 2 |
| Next Q | $-0.71 | $-0.73 — $-0.69 | 71% YoY | 2 |
| Current FY | $-4.20 ▼ -15.6% | $-4.20 — $-4.20 | 25% YoY | 1 |
| Next FY | $-2.85 | $-3.72 — $-1.34 | 32% YoY | 5 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release
May 22, 2026
MIXED
Press
6/10
Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expense
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $425.1M | DOUBLED |
| FMR LLC | $184.2M | NEW |
| BANK OF AMERICA CORP | $70.4M | DOUBLED |
| WELLS FARGO & COMPANY/MN | $99.4K | NEW |
4 institutional holders with $679.8M total value (5,040,677 shares) as of 2025-Q4. Top holders: MORGAN, FMR, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,151,994 | $425.1M | 62.5% | DOUBLED +114.3% |
| 2 | FMR LLC | 1,365,657 | $184.2M | 27.1% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 522,289 | $70.4M | 10.4% | DOUBLED +446.4% |
| 4 | WELLS FARGO & COMPANY/MN | 737 | $99.4K | 0.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 1,470,717 | 3,151,994 | +114.3% | $425.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 95,593 | 522,289 | +446.4% | $70.4M | 2025-Q4 |
| UBS Group AG | DOUBLED | 167,656 | 4,461,262 | +2561.0% | $378.8M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 475,280 | 1,470,717 | +209.4% | $124.9M | 2025-Q3 |
| FMR LLC | NEW | — | 1,430,673 | — | $121.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 536 | 95,593 | +17734.5% | $8.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEW | — | 717 | — | $60.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 10,706 | 536 | -95.0% | $4.1K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 855,676 | 1,373,860 | +60.6% | $8.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 19,736 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 466,429 | 855,676 | +83.5% | $6.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 691 | 174,873 | +25207.2% | $1.3M | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 6 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$155.20 mean target
+27.2% upside
Strong Buy (1.40)
$131.00 Low
$176.00 High
| Metric | Value |
|---|---|
| Current Price | $121.99 |
| Target Low | $131.00 |
| Target Mean | $155.20 |
| Target Median | $155.00 |
| Target High | $176.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.74 | $-0.75 | $-0.73 | 17.2% | -0.5% | 0↑ 1↓ | $0.0B | -65.1% | 2 |
| Next Q 2026-09-30 |
$-0.71 | $-0.73 | $-0.69 | 71.2% | -0.5% | 0↑ 1↓ | $0.0B | -83.4% | 2 |
| Current FY 2026-12-31 |
$-4.20 | $-4.20 | $-4.20 | 24.9% | -15.6% | 0↑ 1↓ | $0.0B | -34.1% | 1 |
| Next FY 2027-12-31 |
$-2.85 | $-3.72 | $-1.34 | 32.1% | -0.3% | 0↑ 1↓ | $0.1B | 3789.2% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.740 | |
| 7d ago | $-0.736 | -0.004 |
| 30d ago | $-0.736 | -0.004 |
| 60d ago | $0.000 | -0.740 |
| 90d ago | $0.000 | -0.740 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 16, 2026 | Jefferies | INITIATE | — | Buy |
| Feb 25, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 24, 2026 | Wedbush | INITIATE | — | Underperform |
| Jan 9, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
earnings
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
<p align="center"><b>Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label
May 6, 2026
Clinical Trial
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Phase Phase 2 — COMPLETED
May 5, 2026
other
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
<p align="center"><b>Abivax</b> <b>Announces Repurchase of </b><b>Royalty Certificates and </b><b>Pricing of $45M (€38.5M) Offering </b><b>of American
Apr 22, 2026
other
Abivax to Present Data on Obefazimod at Digestive Disease Week®
<p align="center"><b>Abivax to Present Data on Obefazimod at </b><b>Digestive Disease Week</b><sup><b>®</b></sup></p>
Apr 20, 2026
other
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
<p align="center"><b>Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026</b><br><b>Availability of the Preparatory Documents</b><
Apr 1, 2026
other
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
<p align="left"><b>Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies</b></p>
Mar 31, 2026
short_interest
FTD: ABVX — 86,183 shares ($8.7M) failed to deliver
Settlement: 20260331, Price: $101.50, FTD Value: $8,747,574.5, ABIVAX SA SPONSORED ADS
Mar 23, 2026
earnings
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><b>Abivax Announces Full Year 2025 Financial Results and Provides </b><b>Business Updates</b></p>
Mar 20, 2026
short_interest
FTD: ABVX — 4,929 shares ($0.6M) failed to deliver
Settlement: 20260320, Price: $123.03, FTD Value: $606,414.87, ABIVAX SA SPONSORED ADS
Feb 23, 2026
short_interest
FTD: ABVX — 86,711 shares ($11.3M) failed to deliver
Settlement: 20260223, Price: $130.35, FTD Value: $11,302,778.85, ABIVAX SA SPONSORED ADS
Feb 10, 2026
short_interest
FTD: ABVX — 14,266 shares ($1.7M) failed to deliver
Settlement: 20260210, Price: $119.78, FTD Value: $1,708,781.48, ABIVAX SA SPONSORED ADS
Feb 5, 2026
short_interest
FTD: ABVX — 5,589 shares ($0.6M) failed to deliver
Settlement: 20260205, Price: $113.57, FTD Value: $634,742.73, ABIVAX SA SPONSORED ADS
Feb 4, 2026
short_interest
FTD: ABVX — 15,019 shares ($1.7M) failed to deliver
Settlement: 20260204, Price: $113.32, FTD Value: $1,701,953.08, ABIVAX SA SPONSORED ADS